| |
n(%)
|
Median (range)
|
Mean ± SD
|
|---|
|
Age, years
| |
48 (17, 78)
|
49 ± 15
|
|
Years since symptom onset
| |
20 (2, 55)
|
23 ± 14
|
|
Present or past iritis
|
37 (54)
| | |
|
Present or past synovitis
|
37 (54)
| | |
|
Patients with a vertebral fracture
|
8 (12)
| | |
|
mSASSS
| |
8 (0, 72)
|
19 ± 21
|
|
BASMI, score
| |
3.0 (1.0, 7.2)
|
3.2 ± 1.6
|
|
BASDAI, score
| |
2.7 (0.2, 7.9)
|
3.1 ± 2.0
|
|
ASDAS, score
| |
2.1 (1.0, 4.4)
|
2.3 ± 0.9
|
|
BAS-G
| |
2.2 (0, 9.8)
|
3.0 ± 2.7
|
|
BASFI, score
| |
2.0 (0, 8.7)
|
2.6 ± 2.2
|
|
ESR, mm/h
| |
10 (2, 73)
|
14 ± 12
|
|
CRP, mg/L
| |
5 (3, 71)
|
9 ± 12
|
|
HLA-B27 positive
|
65 (94)
| | |
|
Patients taking NSAID
|
52 (75)
| | |
|
Patients taking glucocorticoid
|
1 (1)
| | |
|
Patients taking DMARD
|
21 (30)
| | |
|
Methotrexate
|
13 (19)
| | |
|
Sulfasalazine
|
5 (7)
| | |
|
TNF inhibitors
|
15 (22)
| | |
- BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, BAS Functional Index; BASG1, BAS Patient Global score; BASMI, BAS Metrology Index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NSAID, nonsteroidal antiinflammatory drug; DMARD, disease-modifying antirheumatic drug; TNF, tumor necrosis factor; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score.
